Prevention of Diabetes With Pioglitazone in ACT NOW
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 42 of the 42 references it cites were found in a registry or an index.
Abstract
We examined the metabolic characteristics that attend the development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participated in the ACT NOW Study and had complete end-of-study metabolic measurements. Subjects were randomized to receive pioglitazone (PGZ; 45 mg/day) or placebo and were observed for a median of 2.4 years. Indices of insulin sensitivity (Matsuda index [MI]), insulin secretion (IS)/insulin resistance (IR; ΔI0–120/ΔG0–120, ΔIS rate [ISR]0–120/ΔG0–120), and β-cell function (ΔI/ΔG × MI and ΔISR/ΔG × MI) were calculated from plasma glucose, insulin, and C-peptide concentrations during oral glucose tolerance tests at baseline and study end. Diabetes developed in 45 placebo-treated vs. 15 PGZ-treated subjects (odds ratio [OR] 0.28 [95% CI 0.15–0.49]; P < 0.0001); 48% of PGZ-treated subjects reverted to normal glucose tolerance (NGT) versus 28% of placebo-treated subjects (P < 0.005). Higher final glucose tolerance status (NGT > IGT > T2DM) was associated with improvements in insulin sensitivity (OR 0.61 [95% CI 0.54–0.80]), IS (OR 0.61 [95% CI 0.50–0.75]), and β-cell function (ln IS/IR index and ln ISR/IR index) (OR 0.26 [95% CI 0.19–0.37]; all P < 0.0001). Of the factors measured, improved β-cell function was most closely associated with final glucose tolerance status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, changes such as regression to IGT, maintenance of NGT, or progression to diabetes were proportional to insulin secretion response ( 67 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [67]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“from PG and insulin levels obtained during the OGTT (23).”
BackgroundSelf-citationPrevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385 · cited 1×
“The prevalence of type 2 diabetes mellitus (T2DM) has risen to epidemic proportions in the United States and worldwide (1), and is being driven by the epidemic of obesity (2).”
BackgroundDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“In contrast, PGZ does not increase the number of cardiovascular events (31,32).”
BackgroundThe Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456 · cited 2×
“Glucotoxicity has been implicated in progressive b-cell failure as individuals move from NGT to IGT to T2DM (8).”
BackgroundSelf-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 2×
“Alternatively, since PPAR-g is present in muscle/liver and b-cells (10,13), simultaneous PPAR-g activation in these tissues could explain the strong association between improved insulin sensitivity and enhanced b-cell function.”
BackgroundResultYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 2×
“PGZ reduces plasma free fatty acid (FFA) levels, mobilizes fat out of muscle (21) and liver (22), and redistributes fat from visceral to subcutaneous depots (12,16).”
BackgroundSelf-citationPPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Self-citationPrevalence of diabetes and impaired fasting glucose in adults in the U.S. population
Cowie, C. C., Rust, K. F., Byrd-Holt, D. D., Eberhardt, M. S., Flegal, K. M., Engelgau, M. M., Saydah, S. H., Williams, D. E., Geiss, L. S., & Gregg, E. W. (2006) · Diabetes Care · doi:10.2337/dc06-0062 · Cited by 1,210 · cited 1×
“The prevalence of type 2 diabetes mellitus (T2DM) has risen to epidemic proportions in the United States and worldwide (1), and is being driven by the epidemic of obesity (2).”
BackgroundCauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879 · cited 4×
“Treatment with thiazolidinediones improves IS (11) and IR (12–15), ameliorates lipotoxicity (12,14), and redistributes fat from muscle/liver/ b-cells to subcutaneous fat depots (12,16).”
BackgroundInfluentialSelf-citationPioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766 · cited 11×
“From the 1Texas Diabetes Institute, San Antonio, Texas; the 2University of Texas Health Science Center, San Antonio, Texas; 3Phoenix VA Health Care System, Phoenix, Arizona; 4College of Nursing & Health Innovation, Arizona State University, Phoenix, Arizona; the 5State University of New York Health Science Center at B…”
BackgroundInfluentialSelf-citationAbdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744
Self-citationMiyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726 · cited 3×
“Treatment with thiazolidinediones improves IS (11) and IR (12–15), ameliorates lipotoxicity (12,14), and redistributes fat from muscle/liver/ b-cells to subcutaneous fat depots (12,16).”
BackgroundSelf-citationBays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664 · cited 5×
“Treatment with thiazolidinediones improves IS (11) and IR (12–15), ameliorates lipotoxicity (12,14), and redistributes fat from muscle/liver/ b-cells to subcutaneous fat depots (12,16).”
BackgroundInfluentialSelf-citationCauter, E. V., Mestrez, F., Sturis, J., et al. (1992) · Diabetes · doi:10.2337/diabetes.41.3.368 · Cited by 643
Gerstein, H. C., Santaguida, P., Raina, P., Morrison, K. M., Balion, C., Hunt, D., Yazdi, H., & Booker, L. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.05.004 · Cited by 575 · cited 1×
“Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are “high-risk” states with annual diabetes conversion rates ranging from 3 to 11% per year (3).”
BackgroundFerrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540
Self-citationAbdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500
Self-citationPrevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program
The Diabetes Prevention Program Research Group* (2005) · Diabetes · doi:10.2337/diabetes.54.4.1150 · Cited by 474
The Diabetes Prevention Program Research Group (2005) · Diabetes · doi:10.2337/diabetes.54.8.2404 · Cited by 446
Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Kawakubo, M., & Buchanan, T. A. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1066 · Cited by 402 · cited 4×
“These findings are consistent with prior observations in Hispanic women with gestational diabetes mellitus who were treated with troglitazone (9,28) and PGZ (19), and in FIG.”
BackgroundResultInfluentialSelf-citationCavaghan, M. K., Ehrmann, D. A., & Polonsky, K. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10761 · Cited by 362
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2004) · Diabetologia · doi:10.1007/s00125-003-1263-9 · Cited by 338
Self-citationDiabetes and apoptosis: lipotoxicity
Kusminski, C. M., Shetty, S., Orci, L., Unger, R. H., & Scherer, P. E. (2009) · Apoptosis · doi:10.1007/s10495-009-0352-8 · Cited by 302 · cited 1×
“Lipotoxicity (12,14,39) has been implicated in b-cell failure and IR in T2DM.”
BackgroundWeyer, C., Bogardus, C., & Pratley, R. E. (1999) · Diabetes · doi:10.2337/diabetes.48.11.2197 · Cited by 292
Miyazaki, Y., Mahankali, A., Wajcberg, E., Bajaj, M., Mandarino, L. J., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0190 · Cited by 227 · cited 1×
“These effects are mediated, in part, via peroxisome proliferator–activated receptor-g (PPAR-g) receptor (13,20) and via reversal of lipotoxicity (12,14) and changes in adipocytokines (20).”
BackgroundSelf-citationMittelman, S. D., Van Citters, G. W., Kim, S. P., Davis, D. A., Dea, M. K., Hamilton-Wessler, M., & Bergman, R. N. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2116 · Cited by 200 · cited 12×
“Second, insulin MCR was not measured directly, but was inferred from the marked difference in plasma insulin and plasma C-peptide responses.”
BackgroundInfluentialThiazolidinediones improve β-cell function in type 2 diabetic patients
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2006 · Cited by 200
Self-citationNon-esterified fatty acids and the liver: why is insulin secreted into the portal vein?
Bergman, R. N. (2000) · Diabetologia · doi:10.1007/s001250051474 · Cited by 165 · cited 1×
“Elevated plasma FFA levels have been shown to reduce the MCR of insulin (38).”
BackgroundFerrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Pettiti, M., Natali, A., Mari, A., & DeFronzo, R. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1169-6 · Cited by 133
Self-citationActos Now for the prevention of diabetes (ACT NOW) study
DeFronzo, R. A., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Musi, N., Ratner, R., et al. (2009) · BMC Endocrine Disorders · doi:10.1186/1472-6823-9-17 · Cited by 89 · cited 4×
“15 min in Central Laboratory (Texas Diabetes Institute) (17,18).”
BackgroundInfluentialSelf-citationEffects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus
Bajaj, M., Baig, R., Suraamornkul, S., Hardies, L. J., Coletta, D. K., Cline, G. W., Monroy, A., Koul, S., Sriwijitkamol, A., Musi, N., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0911 · Cited by 84 · cited 3×
“The improved insulin sensitivity and IS observed with thiazolidinedione treatment are correlated with weight gain (11,21,40).”
BackgroundSelf-citationAbdul‐Ghani, M. A., Molina‐Carrión, M., Jani, R., Jenkinson, C. P., & DeFronzo, R. A. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0033-z · Cited by 70 · cited 1×
“Adipocyte IR index was calculated as fasting plasma insulin 3 fasting FFA concentration (25).”
MethodSelf-citationPROactive: time for a critical appraisal
Betteridge, D. J., DeFronzo, R. A., & CHILTON, R. J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn114 · Cited by 57 · cited 1×
“In contrast, PGZ does not increase the number of cardiovascular events (31,32).”
BackgroundSelf-citationGastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1479-3 · Cited by 52
Self-citationXiang, A. H., Peters, R. K., Kjos, S. L., Goico, J., Ochoa, C., Marroquin, A., Tan, S., Hodis, H. N., Azen, S. P., & Buchanan, T. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032044 · Cited by 51 · cited 1×
“These findings are consistent with prior observations in Hispanic women with gestational diabetes mellitus who were treated with troglitazone (9,28) and PGZ (19), and in FIG.”
ResultSelf-citationKim, S. H., Abbasi, F., Chu, J. W., McLaughlin, T., Lamendola, C. A., Polonsky, K. S., & Reaven, G. M. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2447 · Cited by 45 · cited 12×
“Second, insulin MCR was not measured directly, but was inferred from the marked difference in plasma insulin and plasma C-peptide responses.”
BackgroundInfluentialMiyazaki, Y., De Filippis, E., Bajaj, M., Wajcberg, E., Glass, L., Triplitt, C., Cersosimo, E., Mandarino, L. J., & Defronzo, R. A. (2005) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/14746514050050010601 · Cited by 18 · cited 1×
“The improved insulin sensitivity and IS observed with thiazolidinedione treatment are correlated with weight gain (11,21,40).”
BackgroundSelf-citationSumner, A. E., Farmer, N. M., Cochran, C. S., Sebring, N. G., Vanevski, K. M., Reynolds, J. C., Premkumar, A., & Boston, R. C. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1978 · Cited by 11
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationAhmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes
Cinti, F., Bouchi, R., Kim-Muller, J. Y., Ohmura, Y., Sandoval, P. R., Masini, M., Marselli, L., Suleiman, M., Ratner, L. E., Marchetti, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2860 · Cited by 550
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · Diabetes Care · doi:10.2337/dc14-0396 · Cited by 460
Tan, S. Y., Mei Wong, J. L., Sim, Y. J., Wong, S. S., Mohamed Elhassan, S. A., Tan, S. H., Ling Lim, G. P., Rong Tay, N. W., Annan, N. C., Bhattamisra, S. K., et al. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.10.008 · Cited by 445
Metadata
- Authors
- DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Gastaldelli, A., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Ratner, R. E., Stentz, F. B., Musi, N., Reaven, P. D., & Study, F. T. A. N.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Phoenix VA Health Care System (US)
- SUNY Downstate Health Sciences University (US)
- Pennington Biomedical Research Center (US)
- University of Southern California (US)
- Georgetown University (US)
- University of California San Diego (US)
- University of Tennessee Health Science Center (US)
- MedStar Health Research Institute (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-10-18
- Volume
- 62
- Issue
- 11
- Pages
- 3920-3926
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3806596
- OpenAlex
- W2103930636
- Cited by
- 109
- References
- 42
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 12 · 2020: 11 · 2019: 6 · 2018: 8 · 2017: 8 · 2016: 11 · 2015: 7 · 2014: 14 · 2013: 2
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Gilead Sciences
- University of Southern California
- Intarcia Therapeutics
- Novo Nordisk
- National Institutes of Health (UL1TR000130)
- Health Science Center, University of Tennessee
- Allergan
- National Center for Research Resources (M01-RR00221)
- National Center for Advancing Translational Sciences
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- pioglitazone, type 2 diabetes prevention, impaired glucose tolerance, insulin sensitivity, Matsuda index, insulin secretion, insulin resistance, beta-cell function, glucose tolerance, thiazolidinediones
- MeSH terms
- Pioglitazone, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Glucose Intolerance, Thiazolidinediones, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.